摘要
目的探讨国产药物支架(DES)对急性ST段抬高型心肌梗死(STEMI)预后的影响。方法对2004-03～2009-04共216例确诊为STEMI的患者分为两组,药物支架(DES)组(n=117)和裸支架(BMS)组(n=99),术后长期随访,观察术后12个月随访终点时支架内再狭窄发生率(ISR)及主要心血管不良事件(包括死亡、急性心肌梗死、靶血管再成形等)发生率。结果 216例患者经皮冠状动脉介入(PCI)治疗均成功。介入治疗3～12个月后随访结果显示,DES组再狭窄率明显低于BMS组(P<0.05),两组心血管不良事件发生率差异无统计学意义(P>0.05)。结论 DES在STEMI患者中有较好的安全性及临床疗效,再狭窄率明显低于BMS(P<0.05)。
Objective To evaluate the safety and effectiveness of firebird drag eluting stentt （DES） in acute ST-segment elevation myocardial infarction. Methods 216 patients with acute ST-segment elevation myocardial infarction from March 2004 to April 2009 were divided into two groups： DES group（n = 117） and BMS group（n =99）. The occurrence rate of in-stentt restenosis （ISR） and major adverse cardiovascular event （sudden death, reinfarction, revascularization） were analyzed after 12 months of implantation. Results Both groups showed a success rate of 100% in stenting. DES group was much better than BMS group in aspect of ISR（P 〈0. 05）. There were no statistic difference in aspect of major adverse cardiovascular event （P 〉 0. 05 ） after 3 to 12 months of implantation. Conclusion DES implanted in patients with acute ST-segment elevation myocardial infarction is safety and effectiveness, DES is much better than BMS in aspect of ISR（P 〈0. 05）.
出处
《中国临床新医学》
2010年第12期1232-1234,共3页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
关键词
药物支架
急性ST段抬高型心肌梗死
再狭窄
心血管事件
Drug-eluting stent
Acute ST-segment elevation myocardial infarction
In-stentt restenosis
Major adverse cardiovascular event
